Reduced Recurrence Rates Are Associated with Photodynamic Diagnostics Compared to White Light after Extended Transurethral Resection of Bladder Tumors.

photodynamic diagnostics recurrence-free survival transurethral resection

Journal

Life (Basel, Switzerland)
ISSN: 2075-1729
Titre abrégé: Life (Basel)
Pays: Switzerland
ID NLM: 101580444

Informations de publication

Date de publication:
26 Apr 2022
Historique:
received: 01 04 2022
revised: 19 04 2022
accepted: 24 04 2022
entrez: 28 5 2022
pubmed: 29 5 2022
medline: 29 5 2022
Statut: epublish

Résumé

One pillar in treating non-muscle-invasive bladder cancer (NMIBC) is the complete and high-quality transurethral resection of the primary tumor (TURBT). However, even after a high-quality primary resection, the residual tumor risk is considerable, thus requiring a re-TURBT. Resections performed with the aid of a photodynamic diagnostics report improved recurrence-free survival rates and increased detection rates of carcinoma in situ (CIS). This monocentric retrospective study reports on patients treated with an extended TURBT procedure using conventional white-light cystoscopy or photodynamic diagnostics (PDD). Only patients undergoing a TURBT resection for their primary tumor were included in the statistical analysis. Recurrence-free survival and overall survival were the clinical endpoints. Mann−Whitney U tests and chi-squared tests were used for descriptive intergroup comparisons. The associations with overall survival and recurrence-free survival were determined by univariate and multivariate analyses. The test results were considered significant when p was < 0.05. In comparison to conventional white-light cystoscopy, PDD increased the detection rates of CIS (p = 0.004) and tumor multifocality (p = 0.005) and led to reduced residual tumor incidence at the primary resection site (p < 0.001). Likewise, tumor recurrence rates were reduced in the PDD cohort (p < 0.001). Patient age and the presence of residual tumor at the primary resection site were identified as independent predictors of overall survival. For recurrence-free survival, only the PDD resection method was an independent predictor (HR = 0.43; p < 0.001). In summary, we demonstrated that the utilization of PDD techniques was associated with improved detection rates of CIS and multifocal tumors and with reduced recurrence rates. The extended resection protocol allowed us to determine that PDD resections lead to a reduced residual tumor rate at the initial resection site. This residual tumor state at the resection site, determined by extended TURBT, became an independent predictor of long-term survival. On the other hand, the PDD technique was confirmed as the only independent predictor of recurrence-free survival.

Identifiants

pubmed: 35629309
pii: life12050641
doi: 10.3390/life12050641
pmc: PMC9143752
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

Int J Technol Assess Health Care. 2011 Jan;27(1):3-10
pubmed: 21262078
Eur Urol. 2010 May;57(5):843-9
pubmed: 19524354
Arch Ital Urol Androl. 2020 Apr 06;92(1):17-20
pubmed: 32255316
Diagnostics (Basel). 2021 Jan 28;11(2):
pubmed: 33525423
Urol Int. 2020;104(5-6):410-416
pubmed: 32209791
Curr Opin Urol. 2020 May;30(3):370-376
pubmed: 32205809
BJU Int. 2011 Feb;107(4):540-6
pubmed: 21276177
Eur Urol. 2013 Feb;63(2):234-41
pubmed: 22877502
Medicine (Baltimore). 2019 Jul;98(28):e16426
pubmed: 31305463
Eur Urol. 2021 Apr;79(4):480-488
pubmed: 33419683
J Urol. 2010 Nov;184(5):1907-13
pubmed: 20850152
Eur Urol. 2010 Apr;57(4):595-606
pubmed: 20004052
Urology. 2009 Dec;74(6):1282-6
pubmed: 19819538
Eur Urol. 2019 Nov;76(5):639-657
pubmed: 31443960
BJU Int. 2012 Jun;109(11):1666-73
pubmed: 22044434
J Urol. 2016 Oct;196(4):1021-9
pubmed: 27317986
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Eur Urol Open Sci. 2021 Jul 22;31:17-27
pubmed: 34467237
Eur Urol. 2006 Mar;49(3):466-5; discussion 475-7
pubmed: 16442208
Int J Clin Oncol. 2020 Jul;25(7):1364-1376
pubmed: 32232691
J Urol. 2003 Aug;170(2 Pt 1):433-7
pubmed: 12853793
BJU Int. 2015 Nov;116(5):721-6
pubmed: 25715815
Eur Urol. 2002 May;41(5):523-31
pubmed: 12074794
Int J Urol. 2020 Dec;27(12):1130-1135
pubmed: 32985754
World J Urol. 2017 Dec;35(12):1871-1877
pubmed: 28803385
Clin Genitourin Cancer. 2019 Aug;17(4):e784-e792
pubmed: 31097388
BJU Int. 2012 Jul;110(2 Pt 2):E76-9
pubmed: 22313727
World J Urol. 2019 Sep;37(9):1867-1877
pubmed: 30535715
Urol Int. 2020;104(5-6):402-409
pubmed: 31910427
World J Urol. 2017 May;35(5):745-752
pubmed: 27604374
Eur Urol. 2016 Feb;69(2):231-44
pubmed: 26091833

Auteurs

Alexander Marquardt (A)

Department of Urology and Pediatric Urology, University Hospital Erlangen, Friedrich-Alexander Universität Erlangen, Krankenhausstrasse 12, 91054 Erlangen, Germany.

Mario Richterstetter (M)

Department of Urology and Pediatric Urology, University Hospital Erlangen, Friedrich-Alexander Universität Erlangen, Krankenhausstrasse 12, 91054 Erlangen, Germany.

Helge Taubert (H)

Department of Urology and Pediatric Urology, University Hospital Erlangen, Friedrich-Alexander Universität Erlangen, Krankenhausstrasse 12, 91054 Erlangen, Germany.
Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany.

Arndt Hartmann (A)

Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany.
Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander Universität Erlangen, Krankenhausstrasse 8-10, 91054 Erlangen, Germany.

Bernd Wullich (B)

Department of Urology and Pediatric Urology, University Hospital Erlangen, Friedrich-Alexander Universität Erlangen, Krankenhausstrasse 12, 91054 Erlangen, Germany.
Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany.

Verena Lieb (V)

Department of Urology and Pediatric Urology, University Hospital Erlangen, Friedrich-Alexander Universität Erlangen, Krankenhausstrasse 12, 91054 Erlangen, Germany.
Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany.

Laura Bellut (L)

Department of Urology and Pediatric Urology, University Hospital Erlangen, Friedrich-Alexander Universität Erlangen, Krankenhausstrasse 12, 91054 Erlangen, Germany.
Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany.

Sven Wach (S)

Department of Urology and Pediatric Urology, University Hospital Erlangen, Friedrich-Alexander Universität Erlangen, Krankenhausstrasse 12, 91054 Erlangen, Germany.
Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany.

Hendrik Apel (H)

Department of Urology and Pediatric Urology, University Hospital Erlangen, Friedrich-Alexander Universität Erlangen, Krankenhausstrasse 12, 91054 Erlangen, Germany.
Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany.

Classifications MeSH